American medical oncology physician (AMOP) preferences for combined modality therapy beginning with systemic management in patients with liver-limited metastatic colorectal cancer (LL-mCRC)

被引：0
|
作者：
Choti, Michael A.
Green, Mark R.
Corral, Mitra
Wong, Schiffon L.
Cairns, Jessica
Thomas, Michele R.
Eaddy, Michael
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Xcenda, Palm Harbor, FL USA
[3] Bristol Myers Squibb, Plainsboro, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.532
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
532
引用
收藏
页数：1
相关论文
共 4 条
  • [1] Patterns of peri-operative systemic therapy in liver-limited metastatic colorectal cancer (mCRC)
    Kellock, Trenton Tyler
    Renouf, Daniel John
    Speers, Caroline
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Population-based patterns of systemic therapy use in liver-limited metastatic colorectal cancer (mCRC)
    Kellock, Trenton Tyler
    Gresham, Gillian
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [3] FOLFOXIRI plus bevacizumab (bev) as upfront treatment for metastatic colorectal cancer (mCRC) patients (pts) with initially unresectable liver-limited disease (LLD)
    Casagrande, M.
    Cremolini, C.
    Zucchelli, G.
    Bergamo, F.
    Ferrari, L.
    Pietrantonio, F.
    Lonardi, S.
    Loupakis, F.
    Masi, G.
    Pella, N.
    Intini, R.
    Salvatore, L.
    Tomasello, G.
    Pagani, F.
    Pellino, A.
    Dell'Aquila, E.
    Ginocchi, L.
    Milione, M.
    Fea, E.
    Pellegrinelli, A.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Phase II study of consolidation treatment with holmium-166 (166Ho) TARE followed by maintenance systemic therapy (MT) in unresectable liver-limited (ULL) colorectal cancer (CRC) patients (pts) after standard first-line induction therapy: The HAITI trial
    Borelli, B.
    Bargellini, I.
    Carullo, M.
    Boni, G.
    Pietrantonio, F.
    Boccaccio, C.
    Antonuzzo, L.
    Conca, V.
    Tamberi, S.
    Taravella, A.
    De Marco, S.
    Rihawi, K.
    Vannini, F.
    Bozzi, E.
    Dell'Aquila, E.
    Bianchi, A. Sartore
    Delliponti, L.
    Cremolini, C.
    Crocetti, L.
    Masi, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S72 - S73
1